- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02954458
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
September 16, 2021 updated by: Shire
A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301
This study will follow participants who completed the TED-C14-006 study.
The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric participants with Short Bowel Syndrome (SBS).
This study will also offer teduglutide treatment to eligible participants, regardless of treatment received in TED-C14-006 or SHP633-301.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Woluwe-Saint-Lambert
-
Bruxelles, Woluwe-Saint-Lambert, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1C9
- Walter C. Mackenzie Health Science Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Helsinki, Finland, 00290
- Helsingin Yliopistollinen Keskussairaala
-
-
-
-
-
Roma, Italy, 00165
- Ospedale Pediatrico Bambino Gesù
-
-
-
-
Greater London
-
London, Greater London, United Kingdom, WC1N 3JH
- Great Ormond Children's Hosp
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Birmingham Children's Hospital
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Mattel Children's Hospital UCLA
-
Los Angeles, California, United States, 90027-6062
- Childrens Hospital Los Angeles - RHU
-
San Francisco, California, United States, 94158-2531
- UCSF Benioff Children's Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown Children's Research Network
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- The Nebraska Medical Center
-
-
New York
-
Bronx, New York, United States, 10467-2403
- Children's Hosp. at Montefiore
-
New York, New York, United States, 07024
- Columbia Unversity Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin School of Medicine and Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant provides written informed consent (participant, parent or legal guardian and, as appropriate, informed assent) to participate in the study before completing any study-related procedures.
- Participant completed the TED-C14-006 or SHP633-301 studies (including participants in the standard of care treatment arms). Participants are considered to have completed SHP633-301 if they completed study assessments through week 24.
- Participant understands and is willing and able to fully adhere to study requirements as defined in this protocol.
Exclusion Criteria:
1. There are no exclusion criteria for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Standard of care (SOC) treatment +/- teduglutide (TED)
Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
|
0.05 mg/kg SC injection once daily.
Standard safety assessments and adjustments in nutritional support.
Teduglutide will be administered using syringe.
Teduglutide will be administered using needle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: From start of study drug administration up to follow-up (up to 46 months)
|
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
TEAEs were defined as AEs that started or worsened on or after the date of first dose of teduglutide for participants in the TED/TED, TED/NTT, and NTT/TED treatment groups, or after the core study baseline visit for participants in the NTT/NTT group.
|
From start of study drug administration up to follow-up (up to 46 months)
|
Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: Total urine output over 48 hours / 2) / body weight (kilogram [kg]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF).
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Average Total Urine Output at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Average total urine output was recorded over a 48 hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
Average daily urine output mL/kg/day was calculated as: (Total urine output over 48 hours/2) / body weight (kg) where total urine output was calculated as the sum of the urine output in mL and the urine-only diaper weights in gram (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF).
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized by the average number of stools per day.
The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2).
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Average Number of Stools Per Day at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized by the average number of stools per day.
The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2).
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized by the average total daily stool/mixed stool diaper weight (gram per kilogram per day [g/kg/day]).
The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day).
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Average Total Daily Stool/Mixed Stool Diaper Weight at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized by the average total daily stool/mixed stool diaper weight (gram per kilogram per day [g/kg/day]).
The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day).
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized the average ostomy output per day (mL/kg/day).
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Average Total Ostomy Output at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized the average ostomy output per day.
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The Average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale.
The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2).
Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces.
Entirely liquid.
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Average Bristol Stool Form Score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Fecal output was recorded over a 48 hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment.
The average daily fecal output was summarized separately the average typical stool form score using Bristol Stool Form Scale.
The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2).
Typical Stool Form based on Bristol Stool Form Scale: 1- Separate hard lumps, hard to pass, 2- Sausage-shaped, but lumpy, 3- Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces.
Entirely liquid.
|
Baseline, Last visit in NT (up to Month 39)
|
Number of Participants With Positive Specific Antibodies at End of Study (EOS)
Time Frame: At EOS (up to 46 months)
|
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
|
At EOS (up to 46 months)
|
Change From Baseline in Body Weight Z-score at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Body weight was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Body Weight Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Body weight was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Height Z-score at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Height was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Height Z-score at Last Visit During Non-Teduglutide Treatment
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Height was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Head Circumference Z-score at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Head circumference was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Head Circumference Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
Head circumference was measured using Z-score.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline in Body Mass Index (BMI) Z-score at EOT of Last Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
BMI Z-score was calculated by using the height and weight data.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, EOT of last cycle (up to Month 36) (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Body Mass Index (BMI) Z-score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
BMI Z-score was calculated by using the height and weight data.
Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population.
Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts are used for calculation.
A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
|
Baseline, Last visit in NT (up to Month 39)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Achieved At Least 20 Percent (%), 50%, and 75% Reduction From Baseline in Diary Parenteral Support (PS) Volume at End of Treatment (EOT) of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Number of participants who achieved at least 20%, 50%, and 75% reduction from baseline in diary PS volume at EOT of last cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Number of Participants Who Achieved At Least 20 Percent (%), 50%, and 75% Reduction From Baseline in Prescribed PS Volume at End of Treatment (EOT) of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Number of participants who achieved at least 20%, 50%, and 75% reduction from baseline in prescribed PS volume at EOT of east cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in diary PS volume at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in diary PS volume at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in prescribed PS volume at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change from baseline in prescribed PS volume at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Diary PS Caloric Intake at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in diary PS caloric intake at EOT of each cycle during teduglutide treatment was reported.
Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Diary PS Caloric Intake at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in diary PS Caloric intake at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Prescribed PS Caloric Intake at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in prescribed PS caloric intake at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Prescribed PS Caloric Intake at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in prescribed PS caloric intake at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Number of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during teduglutide treatment was reported.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Hours Per Day of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in hours per day of diary PS usage at EOT of each cycle during teduglutide treatment was reported.
Hours per day of diary PS was calculated as: Hours per day of actual PS = (sum of hours per day for each day that PS intake data is recorded within the 7 days prior to the visit / number of days that PS hours per day data is recorded as non-zero within the 7 days prior to the visit).
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Hours Per Day of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in hours per day of diary PS usage at EOT of each cycle during teduglutide treatment was reported.
Hours per day of diary PS was calculated as: Hours per day of actual PS = (sum of hours per day for each day that PS intake data is recorded within the 7 days prior to the visit / number of days that PS hours per day data is recorded as non-zero within the 7 days prior to the visit).
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Hours Per Day of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in hours per day of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported.
Hours per day of dairy PS was calculated as: Hours per day of actual PS = (sum of hours per day for each day that PS intake data is recorded within the 7 days prior to the visit / number of days that PS hours per day data is recorded as non-zero within the 7 days prior to the visit).
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Hours Per Day of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in hours per day of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported.
Hours per day of dairy PS was calculated as: Hours per day of actual PS = (sum of hours per day for each day that PS intake data is recorded within the 7 days prior to the visit / number of days that PS hours per day data is recorded as non-zero within the 7 days prior to the visit).
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported.
Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported.
Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported.
Days per week of dairy PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Percent change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported.
Days per week of dairy PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
PedsQL GCS was designed to measure health-related quality of life in pediatric participants and adolescents (2 to 18 years of age).
It encompasses 4 dimensions of functioning (physical [8 items], emotional [5 items], social [5 items], school [3 items]).
Age groups were: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), and Teens (13-18 years).
Depending on the participant's age, the questionnaire may be completed by parent/caregiver as appropriate.
For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young pediatric, and a 5-point Likert scale for the pediatric and teens groups.
Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline In PedsQL GCS Score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
PedsQL GCS was designed to measure health-related quality of life in pediatric participants and adolescents (2 to 18 years of age).
It encompasses 4 dimensions of functioning (physical [8 items], emotional [5 items], social [5 items], school [3 items]).
Age groups were: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), and Teens (13-18 years).
Depending on the participant's age, the questionnaire may be completed by parent/caregiver as appropriate.
For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young pediatric, and a 5-point Likert scale for the pediatric and teens groups.
Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life.
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline In PedsQL Total Family Impact Module Score at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items).
Total family impact score was calculated as the sum of all the items over the number of items answered on all the scales.
Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline In PedsQL Total Family Impact Module Score at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items).
Total family impact score was calculated as the sum of all the items over the number of items answered on all the scales.
Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life
|
Baseline, Last visit in NT (up to Month 39)
|
Change From Baseline In PedsQL Gastrointestinal Symptoms Module at EOT of Each Cycle During Teduglutide Treatment
Time Frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
PedsQL Gastrointestinal symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea.
Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study.
Sub-scale score was calculated as the sum of the items over the number of items answered in the scale.
Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life.
|
Baseline, EOT of each cycle 1, 2, 3, 4, 5, and 6 (Cycles 1, 2, 3, 4, and 5 = 28 weeks, and Cycle 6 = 16 weeks)
|
Change From Baseline In PedsQL Gastrointestinal Symptoms Module at Last Visit During Non-Teduglutide Treatment (NT)
Time Frame: Baseline, Last visit in NT (up to Month 39)
|
PedsQL gastrointestinal symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea.
Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study.
Sub-scale score was calculated as the sum of the items over the number of items answered in the scale.
Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0.
Higher scores indicate improved quality of life.
|
Baseline, Last visit in NT (up to Month 39)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 9, 2017
Primary Completion (ACTUAL)
November 5, 2020
Study Completion (ACTUAL)
November 5, 2020
Study Registration Dates
First Submitted
November 2, 2016
First Submitted That Met QC Criteria
November 2, 2016
First Posted (ESTIMATE)
November 3, 2016
Study Record Updates
Last Update Posted (ACTUAL)
October 13, 2021
Last Update Submitted That Met QC Criteria
September 16, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHP633-304
- 2016-000849-30 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5).
These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD Sharing Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/.
For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short GutUnited States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaNot yet recruitingShort Gut Syndrome
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
Clinical Trials on TED
-
Bispebjerg HospitalUnknown
-
Imperial College LondonNational Institute for Health Research, United KingdomNot yet recruitingSurgery | Venous Thromboembolism
-
University Hospitals Cleveland Medical CenterRecruitingOsteoarthritis Knees BothUnited States
-
US Department of Veterans AffairsCompleted
-
University Health Network, TorontoRecruitingHyperlipidemiasCanada
-
Loyola UniversityCompletedObesity | Shoulder ImpingementUnited States
-
University of HawaiiAlliance for Clinical Trials in OncologyRecruiting
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Viridian Therapeutics, Inc.RecruitingThyroid Eye DiseaseSpain, United States, Netherlands, Germany, Canada, United Kingdom, Italy, Australia, France